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A contribution to breast cancer cell proteomics:
Detection of new sequences
Ductal infiltrating carcinoma (DIC) of the breast is the most common and potentially
aggressive form of cancer. Knowledge of proteomic profiles, attained both in vivo and
in vitro, is fundamental to acquire as much information as possible on the proteins
expressed in these pathologic conditions. We used the breast cancer cell line 8701-
BC, established from a primary DIC, with the aim of contributing to the databases on
mammary cancer cells, which in turn will be very useful for the identification of differ-
entially expressed proteins in normal and neoplastic cells. Within an analysis window
comprising about 1750 discernible spots, we have at present catalogued 84 protein
spots. The proteins for which an identity was assigned were identified essentially using
gel comparison, N-terminal (Nt) microseqencing and immune detection. Among the
protein spots Nt-microsequenced, sixteen corresponded to known proteins, four
resulted as modified, relative to matching sequences deposited on databases, and
seven were unknown. These modified or novel sequences are thus of potential interest
to the knowledge of breast cancer proteomics and its applications.
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1 Introduction
Breast cancer is the most common cancer among Wes-
tern women. However, breast cancer is not a single dis-
ease, but includes several different forms that can be
grouped into invasive and noninvasive histotypes. Among
the invasive, ductal infiltrating carcinoma (DIC) is the most
common and aggressive form [1]. This kind of carcinoma
usually has a poor prognosis, and represents the stan-
dard histotype with which the other less frequent sub-
types are compared. Carcinomas are potentially malig-
nant tumors of epithelial origin, which, once genetically
initiated, grow, progress, invade and spread from one
organ or tissue to another with a common phenotype,
regardless of their individual derivation. The major cellular
changes involved in the conversion of normal to malig-
nant breast are the progressive loss of the stationary epi-
thelial phenotype and the acquisition of a mesenchimal-
like phenotype, correlated with the ability to migrate and
invade surrounding and distant tissues, even under con-
ditions of low oxygen supply. These features are related to
defects in a multiplicity of genes and proteins, whose
number, identity and functions are still far from under-
stood. The proteomic approach is therefore considered
at present to be the most promising to investigate protein
expression and function and to monitor cancer related
defects of large numbers of proteins within a cell or tissue.
However, some limitations to this approach are intrinsic to
the experimental system: on the one hand primary tumor
biopsies may contain several different cell types other
than carcinoma cells, and laser-capture microdissected
sections [2] may include a large amount of proteins resi-
dent in the extracellular interstitium. On the other hand
neoplastic cells in culture, being free of any tissue com-
ponents, may not represent their exact in vivo counter-
parts. In spite of this limitation, cancer cells in culture
represent a powerful substitute for the study of molecular
and cell biology. Therefore, several laboratories, including
our own, have developed appropriate in vitro models of
normal and neoplastic cells for biological and molecular
assays including the recent approach of cDNA micro-
arrays [3] and proteomics [4–7].
Among the breast cancer cell lines described so far in the
literature, 8701-BC [8–10] deserves particular attention,
since it was established from a primary DIC, that is, before
the clonal selection of the metastatic process. This cell
line maintains a number of properties in culture that are
characteristic of mammary tumor cells e.g. expression of
cytokeratin 8 and 18 (typical of the mammary lumenal
phenotype), loss of polarised morphology, accelerated
growth rate, release of matrix metalloproteases, loss of
contact inhibition and formation of multilayered colonies
(domes), low dependence on serum and growth factor
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and the ability to invade matrigel and nude mice. These
properties are clearly distinguished from normal mam-
mary cells in culture (i.e. the HB2 derived from lumenal
epithelial cells [11]), which maintain the polarised pheno-
type, establish correct cell-cell interactions, do not invade
in vitro and in vivo and are dependent on serum. We have
thus used this cell line model for the analysis of protein
expression profiles, with the aim of contributing to the
databases on mammary cancer cells present in the liter-
ature and on the internet, which in turn will be very useful
for the identification of differentially expressed proteins in
normal and neoplastic cells. Within an analysis window
comprising about 1750 discernible spots, we have at
present recorded 84 protein spots, utilising following
methods: N-terminal (Nt) microsequencing (31), immune
detection (23) and gel matching (30) with available
maps at the 2-DE databases (http://www.expasy.ch/
ch2d/2d-index.html). Among the protein spots Nt-micro-
sequenced, sixteen corresponded to known proteins,
four were modified relative to matching sequences de-
posited on databases, seven were unknown and four
were N-blocked.
2 Materials and methods
2.1 Cell culture
For the experiments described, we used the neoplastic
cell line 8701-BC under the conditions previously
described [8]. Briefly, the cells were seeded at a concen-
tration of 1–2  105/cm2 in RPMI 1640 culture medium
(Gibco, Paisley, UK), supplemented with 10% foetal calf
serum (Gibco) and antibiotics (100 units/mL penicillin
and 100 g/mL streptomycin), and grown in a humidified
incubator with 3% CO2 in air at 37C. As nontumoral con-
trol we used the HB2 human mammary epithelial cell line,
kindly given by Dr. J. Taylor-Papadimitriou (Imperial Can-
cer Research Fund, London, UK) and currently cultivated
in our lab under the conditions described by Bartek and
coworkers [11].
2.2 Sample preparations
Cells were grown to confluence and then incubated with
three changes of serum-free medium over 24–48 h. After
washing with ice-cold PBS, they were carefully scraped
and incubated on ice for 30 min with RIPA buffer (50 mM
Tris pH 7.5, 0.1% Nonidet P-40, 0.1% deoxycholate,
150 mM NaCl, 4 mM EDTA and a mixture of protease in-
hibitors, 0.01% aprotinin, 10 mM sodium pyrophosphate,
2 mM sodium orthovanadate, 1 mM PMSF). The total cel-
lular lysate was centrifuged at 14000 rpm for 8 min to
clear cell debris, and the supernatant dialysed against
ultrapure distilled water, lyophilised and stored at –80C
until analysis. Culture media were collected from conflu-
ent cells deprived of serum, extensively dialysed against
ultrapure distilled water; lyophilised and stored at –80C
until used. Protein concentration in the cellular extracts
and culture media was determined using the Bradford
method [12].
2.3 Two-dimensional gel electrophoresis
Aliquots of the dried cell lysate were solubilised in a buffer
containing 4% CHAPS, 40 mM Tris, 65 mM DTE (1,4-
dithioerythritol) and a trace amount of bromophenol blue
in 8 M urea. The first dimensional separation was per-
formed at 20C on commercial sigmoidal immobilised pH
gradient strips (IPGs), 18 cm long with pH range 3.5–10,
(Amersham Pharmacia Biotech, Uppsala, Sweden),
essentially as described by Görg et al. [13] and Bjellqvist
et al. [14]. Strips were rehydrated in 8 M urea, 2% CHAPS,
10 mM DTE and 0.5% carrier ampholytes (Resolyte 3.5–
10; BDH, Merck, Milan, Italy). Aliquots of 45 g (analytical
gels) or 1.5 mg (preparative gels) of total proteins were
applied to the gel strip. IEF was carried out by linearly
increasing the voltage from 200 to 3500 V during the first
3 h, after which focusing was continued at 8000 V for
8 h. After the run the IPG strips were equilibrated with a
solution containing 6 M urea, 30% glycerol, 2% SDS,
0.05 M Tris-HCl pH 6.8 and 2% DTE for 12 min, in order
to resolubilise proteins and reduce disulfur bonds. The
–SH groups were then blocked by substituting the DTE
with 2.5% iodoacetamide in the equilibration buffer. The
focused proteins were then separated on 9–16% linear
gradient polyacrylamide gels (SDS-PAGE) with a constant
current of 40 mA/gel at 10C. Gels were stained with
ammoniacal silver nitrate as described by Hochstrasser
et al. [15].
2.4 Image acquisition and data analysis
Silver stained gels were digitised using a computing den-
sitometer and processed with the Melanie 3 computer
system (GeneBio, Geneva, Switzerland). As internal stan-
dard for gel calibration we used an array of 15 features of
the cell lysate, whose pI and Mr were formerly estimated
by interpolation with serum proteins that had comigrated
with the whole cell lysate. Background subtraction was
performed by considering only the common spots of
three different gels of the same sample matched together.
For figure presentations, images were transferred to
Adobe Photoshop and PowerPoint programs.
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2.5 Protein identification
The proteins for which an identity was assigned were
identified essentially using gel comparison [16], Nt micro-
seqencing and immune detection (see Sections 2.6 and
2.7). For protein identification by computer gel matching
we used the liver map (http://www.expasy.ch/cgi-bin/
map2/def?LIVER_HUMAN), the colorectal adenocarci-
noma DL-1 cell line map (http://www.expasy.ch/cgi-bin/
map2/def?DLD1_HUMAN), the gastrocnemius muscle
map (http://www.expasy.ch/cgi-bin/map2/def?MUSCLE
_MOUSE) deposited in the SWISS-2DPAGE, and the
human breast ductal carcinoma map (http://www.bio-
mol.unisi.it/cgi-bin/map2/def?BREAST_DC_HUMAN) de-
posited in the SIENA-2DPAGE database.
2.6 Protein microsequencing
N-terminal microsequencing was performed by auto-
mated Edman degradation in a protein sequenator (Pro-
cise 491, Applied Biosystems, Monza, Italy) on protein
samples electrotransferred onto PVDF membranes (Milli-
pore, Immobilon-PTM; Sigma, Milan, Italy) at 50 V for
30 min at 4C. The SWISS-PROT (ScanProsite) and EMBL
(Bic 2) databaseswere used foron-linesequence similarity
search at http://www.expasy.ch/tools/#similarity.
2.7 Western blotting
For immune detection the 2-D IPG gels were electro-
transferred onto nitrocellulose membrane (HyBond ECL,
Amersham) at 50 V for 1 h at 4C. After electrotransfer,
the membranes were stained with Ponceau S (Sigma)
and the separation pattern recorded in order to perform
subsequent gel matching. The membranes were then
probed with one of the following monoclonal antibodies:
anti-cytokeratin-8 and 18 (Chemicon International, Milan,
Italy), antivimentin (Novocastra, DBA Italia, Milan, Italy),
and anti-alpha-enolase (courtesy of Prof. S. Feo and col-
leagues, [17]). The reaction was revealed by the ECL
detection system, using high performance films (Hyper-
film ECL, Amersham).
3 Results
In Fig. 1A to C phase contrast micrographs of the 8701-
BC cell culture are shown at 48 h, 1 week and 10 d from
seeding, compared with HB2 cells derived from normal
mammary epithelium at the same growth time (Fig. 1D–F).
As can be observed from these micrographs, the neo-
plastic cells display an apolarised morphology with irreg-
ular profiles; they spread over the substrate with emis-
sion of spikes and once confluence is reached they over-
lap, forming distinctive domes (Fig. 1C). This growth
modality is typical of neoplastic cells and is dramatically
evident when compared with nontumoral cells, which
maintain in vitro the polygonal morphology of epithelial
cells, establish extensive cell-cell contact forming orderly
islands and stop growing once confluent, being respon-
sive to contact inhibition signals.
Since cell morphology is the first manifestation of cell
phenotype and the phenotype of a given cell type is, in
turn, determined by the activation status of its genome
and by the composition of its protein complement in a
given moment of cell life, the proteomic pattern repre-
sents the molecular support for phenotyping cells and
for describing disease associated alterations, which
may involve an unpredictable number of known and
unknown proteins, with structural and functional roles
in the cell. With this aim, we compared the proteomic
profiles of sets of proteins from 8701-BC cells vs. HB2
nontumoral mammary cells reported elsewhere [18].
In the present report we extend previous data with vali-
dation and additional identification of new sets of pro-
teins.
Figure 2 shows the proteomic map of the 8701-BC cell
lysate in which, among the 1750 spots detected by the
Melanie system after background subtraction, we have
identified and catalogued 84 protein spots. The proteins
to which identities were assigned are marked with labels
corresponding to the accession number of the SWISS-
PROT database, which also includes the major isoelectric
variants of assigned proteins. The unknown proteins are
labelled with the abbreviations UBC (unknown breast
cancer) or UBCS (unknown breast cancer secreted),
followed by the approximate molecular mass (kDa). The
last category includes three proteins found in the 2-D
IPG map of the conditioned medium of the 8701-BC
cells, which was matched with the cell lysate map.
Figure 3 shows the 2-D gel section of the conditioned
medium, which includes the Nt-microsequenced spots,
corresponding to the secreted proteins with unknown
identity.
Table I summarises the catalogue of the protein spots
described in Fig. 2 with the following indications: AC and
Entry name, corresponding respectively to the accession
numbers and the abbreviations used in the SWISS-PROT
database, protein name, experimental pI and experimen-
tal Mr, method of protein identification (GM: gel matching
(30), Nt-Mi: N-terminal microsequencing (31), WB: Wes-
tern blot (23)) and N-terminal sequences, along with sub-
stitutions (when present) relative to similar sequences
deposited in the protein databases. Within the proteins
N-terminal sequenced, sixteen corresponded to proteins
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Figure 1. Phase contrast micro-
graphs illustrating the growth
modality of the breast cancer
cell line (8701-BC: A–C) used
for the present research, in com-
parison with nontumoral mam-
mary cells (HB2: D–F) at 48 h,
1 week and 10 d from seeding.
Micrographs were taken from
flask culture with an inverted
microscope. Objective magnifi-
cation 20x (A, C, D, F) and 10x
(B, E).
already present in the databases, four appeared to be
modified relative to the matching proteins, seven resulted
unknown and four were N-blocked.
Among the proteins present in the databases, two have
not been described previously in breast cancer, i.e. the
ubiquitin thiolesterase L1 and the glycoprotein GC1QBP
(MA32). The four proteins showing alterations concerned
thioredoxin, in which the threonine in position 8 is sub-
stituted with alanine; a truncated and slightly more basic
form of annexin I (pI/Mr 8.04/25752, starting from residue
26) displaying two substitutions, namely serine 27 and
glycine 30, both replaced by isoleucine; a truncated form
of alpha-enolase (starting from residue 57) and a short-
ened form of glyceraldehyde 3-phosphate dehydrogen-
ase starting with regular N-terminal residues. In addition,
seven protein sequences, some of which showed ambi-
guities, did not match any known sequence deposited
in the databases. The protein spots released into the
medium by the 8701-BC cells included two unknown
sequences (UBCS) and a small peptide (pI/Mr 5.97/
17100) matching residues 4199-4207 of the perlecan
core protein (PGMB).
Finally, the protein identified by immune detection
regarded an isoelectric series corresponding to alpha-
enolase, coincident with the silver stain pattern, and a
group of intermediate filament proteins. These included
seven spots that bound to anticytokeratin-8, five to anti-
cytokeratin-18 and eight to antivimentin (Fig. 4A–C). In
parallel, the immune detection for intermediate filaments
was also performed on the HB2 cell lysate. In this case
the reaction was negative for the antivimentin assay, and
positive for both anticytokeratins (Fig. 4D–F). However, as
shown in Fig. 4, the number and the isoelectric variants of
both cytokeratins were dissimilar from those observed in
the 8701-BC cell map. As the majority of the cytoskeletal
proteins were almost indiscernible in the silver stained
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Figure 2. 2-D IPG of the total
protein extract from 8701-BC
cells at seven days from seeding
(confluence). Forty-five g of
proteins was loaded on an IPG
gel (18 cm, 3.5–10 NL). The sec-
ond dimension was performed
on a vertical linear-gradient slab
gel (9–16%T). The gel was silver
stained, digitised and analysed
with Melanie 3 software. Protein
spots of known identity are
labelled with the accession
number of the SWISS-PROT
database. The unknown pro-
teins are labelled with the abbre-
viations UBC (unknown breast
cancer) or UBCS (unknown
breast cancer secreted) fol-
lowed by the approximate mass
(kDa).
gels, their attribution to the proteomic map presented in
Fig. 2 was achieved by gel matching with the correspond-
ing pattern on the ECL film.
4 Discussion
Cancer is a somatic gene disease, but at present it is
not known how many genes are directly or indirectly
involved in the transition from normal to malignant cells.
Abnormalities are expected at several levels: gene
alterations, qualitative/quantitative protein expression,
primary and post-translational modifications of protein
structure or cytoplasmic delocalization, any of which
may ultimately affect cell function and behavior. There-
fore the first goal is to obtain the proteomic profiles of
normal and neoplastic cells and tissues and to identify
differentially expressed proteins as putative contributors
to specific malignancies. Hence the proteomic ap-
proach, by allowing the study of variations in gene ex-
pression under a large-scale of magnitude, now repre-
sents a powerful tool to ascertain which protein combi-
nation may play a key role in transformation and tumor
progression and apply the obtained information to new
clinical strategies.
In the present work we aim to provide a contribution to the
knowledge of proteomic profiles of breast cancer using
the well-characterised 8701-BC cell line. As stated in
Section 1, this cell line is derived from a primary DIC and
maintains the phenotypic features of tumorigenic cells in
culture, i.e. the ability to overlap and form distinctive
domes, the loss of polarity and acquisition of motile be-
havior and an invasive capacity both in vitro and in vivo.
Here we demonstrate for the first time that these cells co-
express several forms of cytokeratins (–8 and –18) and
vimentin, which are respectively cytoskeletal markers of
lumenal mammary epithelium [19] and of mesenchimal
cells. These proteins were identified by immune detection
on 2-D IPG gels as multiple forms, many of which are not
included in current databases. The co-expression of cyto-
keratins and vimentin by the 8701-BC cells is a further
demonstration that many features related to cancer cells
(i.e. loss of polarity, defective cell-cell contacts, increased
motility) reflect an epithelial-mesenchymal transition, as
postulated for many carcinomas of different origin [20].
This epithelial-mesenchymal transition is not due to the
in vitro culture, since HB2 cells used as control were
negative for the antivimentin reaction. The proteomic pro-
file of 8701-BC cells, at present a collection of 84 protein
spots, including known proteins, and their isoforms and
924 I. Pucci-Minafra et al. Proteomics 2002, 2, 919–927
Table 1. Catalogue of the protein spots identified in the 2-D IPG map of the 8701-BC reported in Fig. 2. The following are
given: AC and Entry name, corresponding respectively to the accession numbers and the abbreviations used in
the SWISS-PROT database, protein name, isoelectric point and molecular weight, method of protein identifi-










P00367 GDH Glutamate dehydrogenase 1 6.80 49913 GM (Li, Br)
P00367 GDH Glutamate dehydrogenase 1 6.86 49913 GM (Li, Br)
P00938 TPIS Triosephosphate isomerase 6.50 25030 GM (Li, Br)
P00938 TIPIS Triosephosphate isomerase 6.81 25000 Nt-Mi APSRKFFVGG Res. 1–10
P02248 UBIQ Ubiquitin 6.89 8700 GM (Li, Br)
P02570 ACTB Beta-actin 5.16 42000 GM (Li, Br)
O02570 ACTB Beta-actin 5.2042000 GM (Li, Br)
P02570 ACTB Beta-actin 5.23 42000 GM (Li, Br)
P04075 ALFA Fructose-biphosphate aldolase A 7.60 38021 GM (Br)
P04075 ALFA Fructose-biphosphate aldolase A 7.99 38100 GM (Br)
P04083 ANX1 Annexin I 6.94 30530 Nt-Mi XIENEEQEYV Res. 12–21
P04179 SODM Superoxide dismutase [Mn] 6.88 18084 GM (Li, Br)
P04406 G3P2 Glyceraldehyde 3-phosphate
dehydrogenase
7.15 34246 Nt-Mi GKVKVX Res. 1–6
P04406 G3P2 Glyceraldehyde 3-phosphate
dehydrogenase
7.61 35500 Nt-Mi GKVKVGVNGF
Res. 1–10
P04406 G3P2 Glyceraldehyde 3-phosphate
dehydrogenase
8.07 35500 Nt-Mi GKVKVGVNGFGRIGRLV
TRA Res. 1–20
P04406 G3P2 Glyceraldehyde 3-phosphate
dehydrogenase
8.23 35652 Nt-Mi GKVKVGVNGF
Res. 1–10
P04406 G3P2 Glyceraldehyde 3-phosphate
dehydrogenase
8.47 35959 Nt-Mi GKVKVGVNGFGRIGRLV
TRAAFNSGKVDIV
Res. 1–30
P04406 G3P2 tr Glyceraldehyde 3-phosphate
dehydrogenase tr
8.46 34490 Nt-Mi GKVKVGVNGF
Res. 1–10
P05092 CYPH Peptidyl-prolyl cis-trans isomerase A 6.66 14500 GM (Li, Br)
P05092 CYPH Peptidyl-prolyl cis-trans isomerase A 7.07 14500 GM (Li, Br
P05092 CYPH Peptidyl-prolyl cis-trans isomerase A 7.51 14500 GM (Li, Br)
P05217 TBB2 Tubulin beta-2 chain 4.98 49900 GM (Br)
P05783 CK18 Cytokeratin 18 5.05 47074 WB
P05783 CK18 Cytokeratin 18 5.12 48000 WB
P05783 CK18 Cytokeratin 18 5.21 49200 WB
P05783 CK18 Cytokeratin 18 5.23 49300 WB
P05783 CK18 Cytokeratin 18 5.27 49500 WB
P05787 CK18 Cytokeratin 8 5.10 42338 WB
P05787 CK18 Cytokeratin 8 5.14 42600 WB
P05787 CK8 Cytokeratin 8 5.17 43000 WB
P05787 CK8 Cytokeratin 8 5.23 42800 WB
P05787 CK8 Cytokeratin 8 5.25 47000 WB
P05787 CK8 Cytokeratin 8 5.27 43300 WB
P05787 CK8 Cytokeratin 8 5.40 47176 WB
P06576 ATPB ATP synthase beta chain 5.05 49900 GM (DL-1 cells)
P06733 ENOA Alpha enolase 6.41 47074 WB
P06733 ENOA Alpha enolase 6.59 47074 WB
P06733 ENOA Alpha enolase 6.84 47014 WB
P06733 ENOA tr Alpha enolase tr 6.87 41563 Nt-Mi MGKGVSKAVE
Res. 57–66
P08670 VIME Vimentin 5.05 52945 WB
P08670 VIME Vimentin 5.13 53300 WB
P08670 VIME Vimentin 5.01 51055 WB
P08670 VIME Vimentin 5.14 51029 WB
P08670 VIME Vimentin 5.11 51029 WB
P08670 VIME Vimentin 4.93 49900 WB










P08670 VIME Vimentin 4.82 47278 WB
P08670 VIME Vimentin 4.83 42750 WB
P09211 GSTP Glutathione S-transferase P 6.01 20635 Nt-Mi PPYTVVYFPV Res. 1–10
P09936 UBL 1 Ubiquitin thiolesterase L 1 5.34 23940 Nt-Mi MQLKPMEINPEMLV
Res. 1–14
P10599 THIO Thioredoxin 5.01 12579 XKQIESKAAF Res. 1–10
Substitutions: T 8 –A
P10809 HSP 60 60 kDa heat shock protein 5.19 59500 GM (Li, Br)
P10809 HSP 60 60 kDa heat shock protein 5.2359500 Nt-Mi GADAXA Res. 33–38
P10809 HSP 60 60 kDa heat shock protein 5.27 59500 Nt-Mi GADAXA
P11021 GRP 78 78 kDa glucose-regulated protein 4.99 7310 GM (Br)
P11021 GRP 78 78 kDa glucose-regulated protein 5.02 73100 GM (Br)
P11021 GRP 78 78 kDa glucose-regulated protein 5.04 73100 GM (Br)
P13693 TCTP Translationally controlled tumor
protein
4.90 19258 GM (Li, Br)
P14174 MIF Macrophage migration inhibitory
factor
7.62 11900 GM (Br)
P14625 ENPL Tumor rejection antigen 1 4.90 91200 GM (Br)
P14786 KPY 2 Pyruvate kinase M2 7.28 57820 GM (Muscle
Mouse)
P15311 EZRI Ezrin, Cytovillin 6.02 75000 GM (DL-1 cells)
P24534 EF1b Elongation factor 1-beta 4.65 30700 GM (Li, Br)
P27797 CRTC Calreticulin 4.52 59000 GM (Br)
P28066 PSA5 Proteasome subuniut alpha type 5 4.77 25900 Nt-Mi TRSEYDRGVN Res. 4–13
P30101 ERP60 Disulfide isomerase ER-60 5.88 53600 Nt-Mi SDVLELTDDNFE
Res. 25–36
P38646 GRP 75 Mitochondrial stress-70 protein,
Mortalin
5.24 68300 GM (Li, Br)
P38646 GRP 75 Mitochondrial stress-70 protein,
Mortalin
5.28 68300 GM (Li, Br)
P40227 TCPZ T-complex protein 1, zeta subunit 6.39 59000 GM
(DL-1 cells)
P40926 MDHM Malate dehydrogenase 8.03 33835 Nt-Mi AKVAVLGAXG
Res. 25–34
P49411 EFTU Elongation factor Tu 6.50 43300 Nt-Mi AVEAKKTYV Res. 44–52




Q07021 MA32 Glycoprotein GC1QBP 4.54 30387 Nt-Mi LHTEGDKAFV Res. 74–84
ANX tr Annexin I-like 8.04 25752 Nt-Mi XIKGIPGSAV Res. 26–35
Substitutions:
S 27–I; G 30–I
UBC 13 Unknown 4.90 12924 Nt-Mi N-blocked
UBC 14.7 Unknown 5.06 14687 Nt-Mi N-blocked
UBC 14.8 Unknown 7.62 14829 Nt-Mi AYVADLDQ
UBC 14.9 Unknown 8.54 14900 Nt-Mi N-blocked
UBC 26 Unknown 6.76 25606 Nt-Mi N-blocked
UBC 35.5 Unknown 5.25 35500 Nt-Mi ALFQRAR(D/G)
UBC 35.6 Unknown 6.80 35600 Nt-Mi QRQDAQPXQ
UBC 42 Unknown 8.03 42000 Nt-Mi G(HAS)L(LQ)E(IE)TNXPG
UBCS 17 Unknown (perlecan fragment) 5.97 17100 Nt-Mi DAPGQYGAYF
Res. 4199–4207
UBCS 25.6 Unknown 6.54 25635 Nt-Mi XRQXTQIT(Q/F)
UBCS 41 Unknown 5.25 41563 Nt-Mi SXMERAPXRL
GM = gel matching with reference gels present in the SWISS-2DPAGE and SIENA-2DPAGE; Li = Liver, Br = Human breast
ductal carcinoma; DL-1 cells = colorectal adenocarcinoma DL-1 cell line; Muscle mouse = gastrocnemius muscle; WB =
Western blot; Nt-Mi = N-terminal microsequencing; Res = residue.
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Figure 3. 2-D gel section of the 8701-BC cell conditioned
medium, which includes the microsequenced spots
labelled with the abbreviation UBCS as in Fig. 2.
unknown or modified proteins, were identified by means
of N-terminal microsequencing, immune detection and
gel matching with reference gels.
Two of the proteins with known identities have not been
identified before in breast cancer proteomics: the first is
the glycoprotein GC1QBP (MA32), known to bind the
globular heads of C1Q, thus inhibiting C1 activation, but
with unknown function in vivo; the second is UBL1 (ubi-
quitin thiolesterase L1), a thiol protease that removes ubi-
quitin from ubiquitinated proteins and prevents them from
targeted degradation by proteasomes, first described as
a neurospecific marker [21, 22]. A third protein spot, iden-
tified by microsequencing as GST, an enzyme that con-
jugates reduced glutathione to a wide number of exo-
genous and endogenous hydrophobic electrophiles, was
not found to be coincident with the corresponding protein
spot described in breast cancer tissue [23]. Indeed the
latter migrated with a pI/Mr value of 5.40/23325, while on
our map the value was 6.01/20635. This may indicate
that the form identified on our map represents a variant
of that previously described in breast cancer tissue, since
genetic polymorphisms for GSTP1 in breast cancer have
recently been demonstrated [24]. On the other hand,
some authors have reported that the glutathione related
Figure 4. A panel of Western
blots for the immune detection
of cytokeratin-8, cytokeratin-18
and vimentin on 8701-BC cells
(A, B, C) and on HB2 cells (D, E,
F). The reaction to antivimentin
was negative for the HB2
cells, under present conditions.
Ninety g of proteins was
loaded on the IPG gels. The
reaction was revealed by the
method of ECL: the exposed
films were digitised and then
processed by Melanie 3. Each
image of the panel represents
the experimental windows of
the western blot matched with
the corresponding silver stained
gels for the attribution of pI/Mr
coordinates. The position of
beta-actin is reported for refer-
ence.
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detoxification system increases in human breast cancer
in correlation with clinical and histopathological features
[25], and therefore GSTP1 is considered as a potential
marker for breast tumors.
Among the proteins with substitutions we found a
sequence similar to thioredoxin, where the threonine in
position 8 is substituted with alanine. Human thioredoxin
is a small redox protein that is overexpressed in a number
of human primary tumors, where it is associated with
rapid cell proliferation and inhibits apoptosis. Recently
the possible association of thioredoxin with p53-depend-
ent function, including DNA repair in breast cancer, has
been suggested [26].
In addition, two forms of annexin were also identified: one
tagging with the full-length annexin I and the second
starting from Res. 26 (pI/Mr 8.04 25752) and bearing two
substitutions: Ser 27-Ile and Gly 30-Ile. As is known,
annexin is a calcium/phospholipid-binding protein which
promotes membrane fusion and is involved in exocytosis
[27]. It is also known that the ability of annexin I to pro-
mote membrane aggregation is highly dependent on the
structure of theN-terminal domain [28] which includes the
major phosphorylation sites (namely Tyr-20, a site for
phosphorylation by the epidermal growth factor receptor
kinase and Thr-23/Ser-27, the sites for phosphorylation
by protein kinase C in vitro). Therefore it can be deduced
that this truncated form of annexin has a different func-
tion, which remains to be elucidated.
Finally, a truncated form of alpha-enolase (starting from
residue 57, pI/Mr of 6.87/41563) and a shortened form
of glyceraldehyde 3-phosphate dehydrogenase (pI/Mr
8.46/34490) starting with regular N-terminal residues
have been identified. These forms have not been de-
scribed before and, due to the multifunctional role of
both enzymes [29, 30], the appearance of their deriva-
tive peptides in cancer cells is an additional finding of
interest.
The protein spots released by the 8701-BC cells into the
medium included two unknown sequences (UBCS) and a
sequence matching residues 4199–4207 of the perlecan
core protein (PGMB). A proportion of the expressed pro-
teins in the proteomic map of 8701-BC appear to be the
products of novel genes that are absent in the database,
and therefore their inclusion in the database is a further
contribution to the knowledge of breast cancer proteo-
mics.
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